Matricelf
Personalized Platform for Autologous Regenerative Medicine
Company Overview
Snapshot
Founded in April 2019, Matricelf operates with 11–50 employees. The company has raised over $10 million across 4 funding rounds from 2 investors. A significant milestone was achieved in June 2021 when Matricelf became publicly listed on the TASE.
Business overview
Matricelf is a Health Tech & Life Sciences company focused on regenerative medicine. It develops a personalized platform for autologous engineered tissue, utilizing a proprietary decellularization process to create thermo-responsive hydrogels and reprogrammed induced pluripotent stem cells (iPSCs). This technology is designed to differentiate into desired functional tissues, aiming to treat various medical conditions including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction. The company operates within the Pharma & Medical Biotechnology sector, specifically in Biomaterials & Tissue Engineering, serving healthcare providers, biotechnology, and pharmaceutical industries.
Strategic signal
In June 2026, Matricelf advanced towards its first-in-human trial by initiating a GMP manufacturing program and successfully completing a GLP safety study for its personalized engineered tissue implants for spinal cord injury. This signals strong progress in the company's clinical development pipeline and validates its regenerative medicine platform, indicating a potential near-term transition to human trials and significant de-risking for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is Matricelf's core technology?
- Matricelf's core technology involves a proprietary decellularization process that separates stromal cells and extracellular matrix (ECM) from a patient's omental biopsy. This allows for the production of a thermo-responsive hydrogel and the reprogramming of stromal cells into induced pluripotent stem cells (iPSCs), which are then differentiated into functional tissue for regenerative medicine applications.
- When did Matricelf become a public company?
- Matricelf became publicly listed on the TASE in June 2021.
- What recent strategic collaborations has Matricelf announced?
- In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing. Additionally, in March 2026, Matricelf entered a strategic collaboration with Sheba Medical Center to advance its first-in-human clinical program in spinal cord injury.
- What recent progress has Matricelf made regarding its spinal cord implant?
- In June 2026, Matricelf advanced toward its first-in-human trial by initiating a GMP manufacturing program and successfully completing a GLP safety study for its personalized engineered tissue implants for spinal cord injury. In March 2026, Matricelf also reported positive RNA sequencing results demonstrating a promising safety profile of its personalized spinal cord implant.
- Has Matricelf received any recent industry recognition?
- In March 2026, Matricelf was named the Most Innovative Company of 2026 at Advanced Therapies Week in San Diego.